Premium
Possible β‐mannosidosis chimera. Altered expression of metabolic perturbations
Author(s) -
Jones M. Z.,
Cavanagh K. T.,
Kranich R.,
Traviss C.,
Fujita Y.,
Ohta M.,
Matsuura F.
Publication year - 1993
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/bf00711519
Subject(s) - chimera (genetics) , spleen , kidney , biology , transplacental , endocrinology , medicine , phenotype , white matter , fetus , immunology , pregnancy , placenta , biochemistry , genetics , radiology , gene , magnetic resonance imaging
Summary An aberrant β‐mannosidosis phenotype in a 5‐month‐old triplet goat kid was characterized by a late postnatal onset of mild neurological symptoms. Necropsy examination revealed relatively normal myelination; however, the distribution of cytoplasmic vacuolation in the kidney and brain was similar to that observed in neonatal β‐mannosidosis. Variable engraftment of donor stem cells, resulting from transplacental transfusion of stem cells from a normal sibling during the immunotolerant period, may have modified the expected severe β‐mannosidosis phenotype. This investigation was designed to determine the effects of a possible chimeric state on organ‐specific metabolic perturbations. Residual β‐mannosidase enzyme activity was found in plasma, kidney, liver and spleen but not in brain. Other lysosomal enzyme activities were comparable to normal values. Immunoreactive β‐mannosidase was estimated to be less than 10% of normal levels. Kidney, brain grey matter and brain white matter contained 33%, 12% and 4%, respectively, of the oligosaccharides expected in the organs of β‐mannosidosis animals. There were no detectable oligosaccharides or cytoplasmic vacuolation in the liver or spleen. Studies of this possible chimera provided preliminary evidence for the efficacy of prenatal treatment of early‐onset neurodegenerative disorders.